Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach

被引:112
|
作者
Ito, K
Kusuhara, H
Sugiyama, Y
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan
关键词
oral absorption; CYP3A4; P-glycoprotein; diffusion model; drug interaction;
D O I
10.1023/A:1018872207437
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To evaluate the effects of gut metabolism and efflux on drug absorption by simulation studies using a pharmacokinetic model involving diffusion in epithelial cells. Methods. A pharmacokinetic model for drug absorption was constructed including metabolism by CYP3A4 inside the epithelial cells, P-gp-mediated efflux into the lumen, intracellular diffusion from the luminal side to the basal side, and subsequent permeation through the basal membrane. Partial differential equations were solved to yield an equation for the fraction absorbed from gut to the blood. Effects of inhibition of CYP3A4 and/or P-gp on the fraction absorbed were simulated for a hypothetical substrate for both CYP3A4 and P-gp. Results. The fraction absorbed after oral administration was shown to increase following inhibition of P-gp. This increase was more marked when the efflux clearance of the drug was greater than the sum of the metabolic and absorption clearances and when the intracellular diffusion constant was small. Furthermore, it was demonstrated that the fraction absorbed was synergistically elevated by simultaneous inhibition of both CYP3A4 and P-gp. Conclusions. The analysis using our present diffusion model is expected to allow the prediction of in vivo intestinal drug absorption and related drug interactions from in vitro studies using human intestinal microsomes, gut epithelial cells, CYP3A4-expressed Caco-2 cells, etc.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 50 条
  • [1] Effects of Intestinal CYP3A4 and P-Glycoprotein on Oral Drug Absorption—Theoretical Approach
    Kiyomi Ito
    Hiroyuki Kusuhara
    Yuichi Sugiyama
    Pharmaceutical Research, 1999, 16 : 225 - 231
  • [2] Absorption of quinidine is influenced by intestinal P-glycoprotein and CYP3A4 in humans
    Glaeser, H
    Drescher, S
    Mürdter, T
    Eichelbaum, M
    Fromm, MF
    DRUG METABOLISM REVIEWS, 2003, 35 : 66 - 66
  • [3] Functional interaction of intestinal CYP3A4 and P-glycoprotein
    Kivistö, KT
    Niemi, M
    Fromm, MF
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (06) : 621 - 626
  • [4] Predicting Drug-Drug Interactions Involving the Inhibition of Intestinal CYP3A4 and P-Glycoprotein
    Tachibana, Tatsuhiko
    Kato, Motohiro
    Takano, Junichi
    Sugiyama, Yuichi
    CURRENT DRUG METABOLISM, 2010, 11 (09) : 762 - 777
  • [5] Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4
    Cummins, CL
    Jacobsen, W
    Benet, LZ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (03): : 1036 - 1045
  • [6] The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4
    Wang, Xianming
    Zhang, Xiang
    Huang, Xinhui
    Li, Yuntong
    Wu, Mengchao
    Liu, Jingfeng
    XENOBIOTICA, 2016, 46 (07) : 651 - 658
  • [7] Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from their In Vitro Km Values
    Tachibana, Tatsuhiko
    Kato, Motohiro
    Sugiyama, Yuichi
    PHARMACEUTICAL RESEARCH, 2012, 29 (03) : 651 - 668
  • [8] Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from their In Vitro Km Values
    Tatsuhiko Tachibana
    Motohiro Kato
    Yuichi Sugiyama
    Pharmaceutical Research, 2012, 29 : 651 - 668
  • [9] Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein
    Tachibana, T.
    Kato, M.
    Watanabe, T.
    Mitsui, T.
    Sugiyama, Y.
    XENOBIOTICA, 2009, 39 (06) : 430 - 443
  • [10] Impact of saturation of CYP3A4 and P-glycoprotein in vivo on the prediction of intestinal availability
    Gertz, Michael
    Harrison, Anthony
    Davis, John
    Houston, J. Brian
    Galetin, Aleksandra
    DRUG METABOLISM REVIEWS, 2009, 41 : 29 - 30